BioSpace News Archive

Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit to be held October 27-28, 2021.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into an exclusive worldwide license agreement with Dana-Farber Cancer Institute (Dana-Farber) and a sponsored research agreement (SRA) with Stanford Medicine for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) designed for the treatment of EGFR-mutant lung cancers.

G1 Therapeutics, Inc. will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET.

Kymera Therapeutics, Inc. today announced that the Company will hold a webcast and conference call to review the data from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers to be presented at the 4th Annual Targeted Protein Degradation Summit

Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species.

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE.

AXIM Biotechnologies, Inc. today announced it has appointed Kelly K. Nichols, O.D., M.P.H., Ph.D. to its Medical Advisory Board. Dr. Nichols joins AXIM’s three other new Advisory Board members, including doctors Henry D. Perry , Laura Periman , and Chairman Joseph Tauber .

Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world’s most prevalent eye diseases, today announced publication in the journal Cornea of positive results from OLYMPIA, a multicenter, investigator-masked, randomized controlled trial.

TCR 2 Therapeutics Inc. today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET.